LRRK2 and preventive therapies in Parkinson disease
Speakers
Department of Pathology, Haukeland University Hospital, Bergen, Norway
Department of Biomedicine, University of Bergen, Bergen, Norway
Abstract
The discovery that pathogenic mutations in the LRRK2 gene increase LRRK2 kinase activities and that small molecule LRRK2 kinase inhibitors blocking these activities can be neuroprotective in preclinical PD models have placed LRRK2 at the center of disease modification efforts in PD. Recent investigations suggest also that LRRK2 may play a role in the pathogenesis of iPD. In my talk I shall review the steps that led to the discovery that LRRK2 mutations can cause PD, and the characteristics of LRRK2-PD that are most relevant for LRRK2-targeted therapies and clinical trials. Challenges that lie ahead in implementing disease modification trials in LRRK2 mutation carriers will be discussed.
Host
Prof. Dr. Rejko Krüger
LOCATION
Online *
* For onsite registration please send an email to bianca.dragomir@lih.lu
To join the Webinar: Cisco Webex
Event number: 2784 968 3894
Event password: 4nWJmKKeW42
(46956553 when dialing from a phone or video system)
Join by phone: +352-2730-0072
Luxembourg Toll
Access code: 278 496 83894
LECTURE: 04:00 PM – 05:00 PM
DATA PRIVACY
Read more about the “Data Protection Notice: processing of personal data in the scope of events’ management”.
